The federal marijuana rescheduling hearing heard Monday from a witness whose profession sits squarely in the path of the government’s proposal: a licensed California pharmacist who told the court that the plant the government wants to treat as medicine cannot meet the standards that define an actual drug.
The witness was Phil Drum, a California pharmacist who delivered his account in a presentation format. A single through-line held his testimony together: the controls that govern real medicine are simply absent from the marijuana marketplace.
He began with the pharmacology. Marijuana, Drum testified, carries a long list of adverse effects and drug-drug interactions, the kind a pharmacist is obligated to catch and disclose before a patient is ever handed a product. State cannabis programs do nothing meaningful to surface them, and the “budtenders” at the counter have no clinical training to fill the gap. What passes for counseling there, he said, is not medical advice at all.
Drum also flagged how the products are sold: THC edibles routinely packaged to mimic familiar consumer brands, blurring the line between a controlled intoxicant and a snack a child would recognize. And he pointed to the human stakes, testifying that veterans who do not use marijuana take their own lives at roughly half the rate of those who do.
Perhaps most damaging to the government’s “medicine” framing was Drum’s account of recalls. When marijuana products are pulled from shelves, he said, the notices reveal what is actually in them—mold, bacteria, pesticides, and other contaminants. And unlike an FDA recall, which moves swiftly to pull tainted product, marijuana recalls are handled slowly and unevenly. A real medicine, the point went, does not work this way.
The hearing resumes tomorrow with the second witness in Drum’s presentation, Dr. Karen Randall, a physician expected to testify about her experience treating patients suffering from cannabis use disorder.